Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody
出版年份 2018 全文链接
标题
Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody
作者
关键词
-
出版物
CANCER BIOLOGY & THERAPY
Volume -, Issue -, Pages 1-13
出版商
Informa UK Limited
发表日期
2018-08-25
DOI
10.1080/15384047.2018.1507258
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer
- (2018) Christopher J. Halbrook et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells
- (2018) Laurence Booth et al. CANCER BIOLOGY & THERAPY
- KRAS Mutation and Epithelial-Macrophage Interplay in Pancreatic Neoplastic Transformation
- (2018) Faraz Bishehsari et al. INTERNATIONAL JOURNAL OF CANCER
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Combination Immunotherapy in Non-small Cell Lung Cancer
- (2018) Melina E. Marmarelis et al. Current Oncology Reports
- Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages
- (2018) Amber E. de Groot et al. Oncotarget
- Immunotherapy in mucosal melanoma: a case report and review of the literature
- (2018) Hana Studentova et al. Oncotarget
- Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders?
- (2018) Luca Parisi et al. Journal of Immunology Research
- Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends
- (2018) Phyllis F. Cheung et al. Oncology Research and Treatment
- Immunological Approaches Towards Cancer and Inflammation: A Cross Talk
- (2018) Xinglong Qu et al. Frontiers in Immunology
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
- (2018) Judith A. Seidel et al. Frontiers in Oncology
- Targeting Macrophages in Cancer: From Bench to Bedside
- (2018) Ashleigh R. Poh et al. Frontiers in Oncology
- Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
- (2017) Shalin Shah et al. Oncotarget
- HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
- (2017) Laurence Booth et al. Oncotarget
- [Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration
- (2017) Laurence Booth et al. Oncotarget
- HDAC inhibition potentiates immunotherapy in triple negative breast cancer
- (2017) Manuela Terranova-Barberio et al. Oncotarget
- HDAC inhibitors enhance the immunotherapy response of melanoma cells
- (2017) Laurence Booth et al. Oncotarget
- The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
- (2017) Laurence Booth et al. Oncotarget
- Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
- (2015) L. Zhai et al. CLINICAL CANCER RESEARCH
- Bioengineered Human Arginase I with Enhanced Activity and Stability Controls Hepatocellular and Pancreatic Carcinoma Xenografts
- (2014) Evan S. Glazer et al. Translational Oncology
- Arginase II Expressed in Cancer-Associated Fibroblasts Indicates Tissue Hypoxia and Predicts Poor Outcome in Patients with Pancreatic Cancer
- (2013) Yoshinori Ino et al. PLoS One
- Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer
- (2011) P. Goedegebuure et al. CURRENT CANCER DRUG TARGETS
- Dishevelled interacts with the DIX domain polymerization interface of Axin to interfere with its function in down-regulating β-catenin
- (2011) Marc Fiedler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation
- (2010) Margaret A. Park et al. CANCER BIOLOGY & THERAPY
- Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+-De novo Ceramide-PP2A-Reactive Oxygen Species-Dependent Signaling Pathway
- (2010) M. A. Park et al. CANCER RESEARCH
- Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
- (2010) H. K. Koblish et al. MOLECULAR CANCER THERAPEUTICS
- Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
- (2009) Bryan T. MacDonald et al. DEVELOPMENTAL CELL
- Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation
- (2008) G. Zhang et al. CLINICAL CANCER RESEARCH
- Transmembrane Helix Uniformity Examined by Spectral Mapping of Torsion Angles
- (2008) Richard C. Page et al. STRUCTURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started